How to Achieve Healthy Births via IVF in Georgia - A Guide to Healthy Offspring with IVF in Georgia

1. Real Questions from the Clinic: The Desire for Healthy Offspring of a 38-Year-Old Couple

A 38-year-old woman and her 41-year-old husband entered the consultation room with their test reports. The woman's AMH was 1.2 ng/mL, antral follicle count was 6, and FSH was 10.5 IU/L. The man's semen analysis showed a concentration of 15×10⁶/mL, 28% progressively motile sperm, and 4% normal morphology.

They have been married for 6 years and have been trying to conceive for 2 years without success. They want a child and are particularly concerned about the child's health. They asked, "Doctor, we want to achieve a healthy birth. What about going to Georgia for IVF?"

This is a question that needs to be answered from three dimensions: reproductive medicine, genetics, and legal policy.

2. From a Reproductive Medicine Perspective: The Relationship Between IVF in Georgia and Healthy Offspring

The core meaning of healthy offspring in the field of assisted reproduction is to reduce the risk of birth defects through technical means and increase the probability of a healthy live birth. The core tool provided by IVF in Georgia for this purpose is Preimplantation Genetic Testing (PGT).

Three Types of PGT and Their Role in Healthy Offspring

Georgian law explicitly allows the clinical application of PGT technology, providing a technical possibility for families with genetic risks to achieve healthy offspring. However, it must be clarified: PGT cannot detect all genetic diseases, nor can it guarantee 100% embryo health; it reduces specific types of genetic risks.

3. When is it Suitable to Go to Georgia for IVF to Achieve Healthy Offspring?

• Carriers of Chromosomal Abnormalities: If one partner has a balanced chromosomal translocation, Robertsonian translocation, or inversion, PGT-SR can screen for embryos with normal structure.
• Carriers of Monogenic Genetic Diseases: If both partners are known carriers of the same recessive genetic disease (e.g., thalassemia, spinal muscular atrophy), PGT-M can screen for unaffected embryos.
• Advanced Maternal Age (≥38 years): The rate of chromosomal aneuploidy in eggs increases significantly with age. PGT-A can screen for chromosomally normal embryos, reducing miscarriage rates.
• Repeated Implantation Failure or Recurrent Miscarriage: After excluding uterine factors, embryonic chromosomal abnormalities are a major cause. PGT-A helps select euploid embryos.
• Family History of Genetic Diseases: After genetic counseling, a clear pathogenic gene is identified, and this gene can be detected via PGT-M.

4. When is it Unsuitable or Requires Careful Consideration?

• Severely Diminished Ovarian Reserve: AMH below 0.5 ng/mL, antral follicle count less than 3. The number of eggs retrieved may be very low, and the probability of forming detectable embryos is low.
• No Clear Medical Indication: Undergoing PGT solely to "increase success rates" or "ensure a perfect child" offers limited medical benefit and carries the risk of embryo loss.
• Limited Financial Resources: PGT testing costs are high, and there is a possibility of having no embryos available for transfer. Financial and psychological preparation is necessary.
• Insufficient Time: From initial tests to final transfer, it typically takes 3-6 months, requiring multiple trips or a longer stay.

5. Age-Related Differences and Key Decision Points

Age is the most critical factor affecting egg quality and chromosomal abnormality rates. For a 38-year-old woman, the embryo chromosomal abnormality rate is approximately 40-50%. PGT-A can help screen for chromosomally normal embryos, increasing the success rate per single transfer and reducing the risk of miscarriage.

6. Comparison of Differences Between Georgia and Other Countries

In the field of assisted reproduction, legal policies, technical levels, and cost structures vary significantly between countries. Georgia has certain characteristics, but it is not suitable for everyone.

• Legal Aspect: Georgia allows PGT, egg and sperm donation, and the legal environment is relatively clear. Compared to the US, Georgia has more relaxed legal protection for embryos and greater operational flexibility.
• Technical Level: The quality of PGT laboratories in Georgia varies. It is essential to choose a laboratory with international accreditation (e.g., CAP, ISO). Compared to top US reproductive centers, there may be differences in the depth and precision of NGS (Next-Generation Sequencing).
• Cost Aspect: Overall costs in Georgia are about 1/3 to 1/2 of those in the US, and PGT testing fees are relatively lower. However, lower cost does not necessarily mean higher cost-effectiveness; laboratory quality must be comprehensively evaluated.
• Process Complexity: Obtaining a medical visa for Georgia is relatively simple, and stay requirements are flexible. However, extra attention is needed regarding language communication, translation of legal documents, and embryo transport (if required).

7. Actual Process and Timeline

Standard Process (Using PGT-A as an Example)

1. Preliminary Tests (Completed domestically, 1-2 months): Woman: AMH, FSH, LH, Estradiol, Antral Follicle Count, Chromosome Karyotype, Genetic Disease Carrier Screening. Man: Semen Analysis, Chromosome Karyotype, Genetic Disease Carrier Screening. Both: Infectious Disease Screening (HIV, Hepatitis B, Hepatitis C, Syphilis, etc.).
2. Remote Consultation and File Creation (2-4 weeks): Submit test reports, have a video consultation with a Georgian doctor, confirm the plan, and sign informed consent. Prepare passport (valid for more than 6 months), notarized and translated marriage certificate.
3. Visa Application (1-2 weeks): Georgian e-visa or regular visa.
4. Travel to Georgia for Ovarian Stimulation (12-14 days): Start ovarian stimulation on day 2-3 of menstruation, monitor follicle development regularly, egg retrieval after about 10-12 days.
5. Egg and Sperm Retrieval and Embryo Culture (5-6 days): After egg retrieval, combine with sperm, culture to blastocyst stage (day 5-6).
6. PGT Testing (2-4 weeks): Biopsy the blastocyst and send for genetic testing. Embryos are cryopreserved during testing.
7. Frozen Embryo Transfer (1-2 months): After results are available, select a transferable euploid embryo, prepare the endometrium and transfer in the next menstrual cycle.
8. Luteal Phase Support and Pregnancy Test (2 weeks): Use luteal phase support medication after transfer, test blood HCG on day 12-14.

The entire cycle from initial tests to final transfer typically takes 3-6 months. If multiple egg retrievals are needed to accumulate embryos, the time will be longer.

8. Interpretation of Key Examination Indicators

• AMH (Anti-Müllerian Hormone): Reflects ovarian reserve, not affected by the menstrual cycle. 1.0-4.0 ng/mL is the normal range; below 1.0 indicates diminished reserve; below 0.5 indicates severely diminished reserve.
• FSH (Follicle-Stimulating Hormone): Tested on day 2-3 of menstruation. Above 10 IU/L indicates diminished ovarian reserve; above 15 IU/L indicates a high risk of poor response.
• LH (Luteinizing Hormone): An abnormal ratio with FSH (>2-3) may suggest Polycystic Ovary Syndrome (PCOS).
• Antral Follicle Count (AFC): Ultrasound on day 2-3 of menstruation. Total antral follicle count in both ovaries less than 5-7 indicates diminished reserve.
• Chromosome Karyotype: Detects whether either partner has chromosomal numerical or structural abnormalities. It is the basis for PGT-SR and PGT-M.
• Genetic Disease Carrier Screening: Recommended before planning pregnancy, especially for those with a family history or from high-prevalence regions.

9. Most Easily Overlooked Details

• Passport Validity: Ensure the passport is valid for more than 6 months and is undamaged. Georgia has specific requirements for passport validity upon entry.
• Translation and Notarization of Test Reports: Some Georgian hospitals require domestic test reports to be notarized or certified by a designated translation agency. Confirming in advance can avoid back-and-forth travel.
• Stability of Embryo Biopsy: PGT testing requires the embryo to develop to the blastocyst stage and undergo biopsy. Not all embryos reach the biopsy standard. With few eggs retrieved or poor embryo quality, there may be no embryos to test.
• Luteal Phase Support After Transfer: The luteal phase support medications used in Georgia may differ from those domestically. Communicate clearly in advance and use under a doctor's guidance.
• Signing Legal Documents: Documents involving embryo disposition rights, informed consent for egg/sperm donation, etc., need to be read and understood carefully. Seek legal counsel if necessary.

10. Doctor's Advice

For couples aiming to achieve healthy offspring through IVF in Georgia, the following steps are recommended for rational decision-making:

1. Complete a Comprehensive Fertility Assessment: Including ovarian reserve, semen quality, chromosome karyotype, and genetic disease carrier screening. This is the basis for determining suitability for PGT.
2. Undergo Professional Genetic Counseling: Clarify whether there is a genetic risk requiring PGT intervention, and understand the limitations and uncertainties of PGT.
3. Compare Laboratory Quality Across Multiple Institutions: Look beyond cost; focus on the laboratory's accreditation, biopsy techniques, testing platforms, and clinical data.
4. Prepare Mentally and Financially: A PGT cycle may result in no embryos available for transfer. Accept this possibility in advance. Besides medical costs, consider additional expenses for travel, accommodation, translation, etc.
5. View Healthy Offspring Rationally: IVF and PGT technology can reduce specific genetic risks but cannot eliminate all risks. Achieving healthy offspring is a systematic project involving pre-pregnancy nutrition, environmental factors, prenatal checks, and more.

11. Risk Reminder

PGT technology itself carries a certain risk of embryo loss (the biopsy procedure may damage the embryo or cause it to stop developing), and the test results have a certain rate of false positives and false negatives (approximately 1-2%). Embryos with normal PGT-A results may still show other abnormalities in subsequent prenatal checks. Therefore, PGT cannot replace prenatal screening and prenatal diagnosis.

Additionally, Georgia's medical regulatory system differs from that of other countries. It is advisable to choose a laboratory with international accreditation and fully understand local legal regulations and medical dispute resolution mechanisms before making a decision.